| Targets |
(+)-Cloprostenol isopropyl ester targets the FP receptor (prostaglandin F receptor), a G protein-coupled receptor that is activated by PGF2α. As an agonist, it binds to the FP receptor and activates downstream signaling pathways, primarily involving the activation of phospholipase C and the subsequent increase in intracellular calcium levels. This leads to the contraction of smooth muscle and the induction of luteolysis, the functional and structural regression of the corpus luteum.
|
|---|---|
| ln Vitro |
In vitro, (+)-Cloprostenol isopropyl ester acts as a FP receptor agonist with a Ki of 28 nM. Its activity is confirmed through receptor binding and functional assays. As a PGF2α analog, it mimics the biological actions of the natural ligand, leading to similar downstream signaling events. Its potency as a luteolytic agent is a direct result of its high affinity for the FP receptor.
|
| ln Vivo |
Changes in spermatogenesis and spermatogenesis evolution are induced by cloprostenol isopropyl ester (25 μg/kg; intraperitoneal injection; once daily for 4 weeks; male mice) [1]. Cats' pupils constrict when injected with cloprostenol isopropyl ester (1 μg, 30 μL) for 2, 4, or 6 hours. In monkeys treated with lasers, cloprostenol isopropyl ester effectively lowers intraocular pressure [2].
In vivo, (+)-Cloprostenol isopropyl ester is a potent luteolytic agent used in veterinary medicine. It induces luteal dissolution in mares during the luteal phase without causing clinical side effects or stress responses. It is also used to terminate pregnancy and for estrus synchronization in various livestock species. Its isopropyl ester form enhances its absorption and bioavailability, making it an effective veterinary drug. |
| Enzyme Assay |
Non-cell-based receptor binding assays for (+)-Cloprostenol isopropyl ester involve radioligand binding studies using membrane preparations from cells expressing the FP receptor. The receptor is incubated with a radiolabeled PGF2α ligand and varying concentrations of the compound. Its binding affinity (Ki) is determined by measuring the displacement of the radiolabeled ligand. Functional activity can be assessed using GTPγS binding assays.
|
| Cell Assay |
Cellular assays for (+)-Cloprostenol isopropyl ester are performed using cells expressing the FP receptor. Cells are treated with the compound, and downstream signaling, such as calcium mobilization or inositol phosphate production, is measured. The compound's ability to activate the receptor and its potency (EC₅₀) is determined. These assays confirm its functional activity as an agonist.
|
| Animal Protocol |
Animal/Disease Models: Male mice (50-80 days) [1]
Doses: 25 μg/kg Route of Administration: intraperitoneal (ip) injection; one time/day for 4 weeks Experimental Results: Stimulates androgen synthesis in a time-dependent manner. In vivo animal models for (+)-Cloprostenol isopropyl ester include studies in rats, hamsters, and mares to assess its luteolytic activity. The compound is administered via appropriate routes (e.g., intramuscular or subcutaneous), and its effects on the corpus luteum, progesterone levels, and estrus cycle are measured. These studies confirm its efficacy as a luteolytic agent and its suitability for veterinary use. |
| ADME/Pharmacokinetics |
(+)-Cloprostenol isopropyl ester has a molecular weight of 462.60 g/mol and a molecular formula of C₂₅H₃₅ClO₆. Its CAS number is 157283-66-4. The compound is supplied as an ethanol solution. It is a synthetic analog of PGF2α and an FP receptor agonist with a Ki of 28 nM. Storage conditions: -20°C. Detailed pharmacokinetic parameters such as half-life and bioavailability are not extensively reported.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for (+)-Cloprostenol isopropyl ester are not extensively reported in the available literature. As a veterinary drug, its safety profile has been established in target animals. Potential side effects may include transient discomfort at the injection site and, rarely, other systemic effects. The compound is intended for research use only in the context of this request and is not for human consumption. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
(+)-Cloprostenol isopropyl ester is a synthetic analog of prostaglandin F2α (PGF2α) and an FP receptor agonist with a Ki of 28 nM. It is a potent luteolytic agent in rats and hamsters. The compound is extensively used in veterinary medicine to induce luteolysis and for estrus synchronization in livestock. Its CAS number is 157283-66-4.
|
| Exact Mass |
466.212
|
|---|---|
| CAS # |
157283-66-4
|
| PubChem CID |
59938277
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.227±0.06 g/cm3
|
| LogP |
4.062
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
32
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
5
|
| InChi Key |
OCNSAYQJDKJOLH-AHTXBMBWSA-N
|
| InChi Code |
InChI=1S/C25H35ClO6/c1-17(2)32-25(30)11-6-4-3-5-10-21-22(24(29)15-23(21)28)13-12-19(27)16-31-20-9-7-8-18(26)14-20/h3,5,7-9,12-14,17,19,21-24,27-29H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
|
| Chemical Name |
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
|
| Synonyms |
(+)-Cloprostenol isopropyl ester.; (+)-16-m-chlorophenoxy tetranor Prostaglandin F2α isopropyl ester
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
